산후 우울증 - 시장 인사이트, 역학, 시장 예측(2036년)

Key Highlights:

• The Postpartum Depression Treatment Market Size in the 7MM was estimated to be USD 260 million in 2023.
• Among EU4 and the UK, the UK accounted for the highest Postpartum Depression Market Size of ~USD 25 Million in 2023.
• In 2025, the total diagnosed prevalent cases of maternal PPD in the 7MM were approximately 1.3 million, and this number is expected to rise during the forecast period, driven by increased awareness, improved screening and diagnosis, as well as factors such as pandemic-related stress, economic pressures, and reduced social support.
• Postpartum Depression (PPD) is the most common non-psychotic complication of childbearing women. It can interfere with normal maternal-infant bonding and adversely affect acute and long-term child development.
• Postpartum Depression is diagnosed when at least five depressive symptoms are present for at least 2 weeks. In the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), PPD is considered when a patient has a major depressive episode along with the peripartum onset, and it is not mentioned as a separate disease.
• Screening for Postpartum Depression can be done 2-6 months after childbirth. Women with Postpartum Depression should also be assessed for manic features. Several screening tools are available, and one of the most frequently used is the Edinburgh Postnatal Depression Scale (EPDS).
• Selective serotonin reuptake inhibitors (SSRIs) are the traditional first choice. Antidepressant medication in combination with therapy is recommended for women with moderate-to-severe depression.
• ZURZUVAE (zuranolone) and ZULRESSO (brexanolone) are the sole approved medications for postpartum depression (PPD). Zulresso is administered as a continuous intravenous (IV) infusion while the recommended dosage for ZURZUVAE is 50 mg orally for 14 days. Key Postpartum Depression Companies in developing emerging PPD therapies include Sage Therapeutics, Marinus Pharmaceuticals, Lipocine, and Brii Biosciences.

Postpartum Depression Treatment Market Report: Summary

• The Postpartum Depression drugs market report offers extensive knowledge regarding the epidemiology segments and predictions, presenting a deep understanding of the potential future growth in diagnosis rates, disease progression, and treatment guidelines. It provides comprehensive insights into these aspects, enabling a thorough assessment of the subject matter.
• Additionally, an all-inclusive account of the current Postpartum Depression management market techniques and emerging therapies and the elaborative profiles of late-stage (Phase III and Phase II) and prominent therapies that would impact the current Postpartum Depression treatment market landscape and result in an overall market shift has been provided in the report.
• The Postpartum Depression drugs market report also encompasses a comprehensive analysis of the Postpartum Depression therapeutics market, providing an in-depth examination of its historical and projected market size (2022-2036). It also includes the Postpartum Depression market share of therapies, detailed assumptions, and the underlying rationale for our methodology. The Postpartum Depression therapeutics market report also includes drug outreach coverage in the 7MM region.
• The Postpartum Depression drugs market report includes qualitative insights that provide an edge while developing business strategies, by understanding trends, through SWOT analysis and expert insights/KOL views, including experts from various hospitals and prominent universities, patient journey, and treatment preferences that help shape and drive the 7MM Postpartum Depression drugs market.

Postpartum Depression Market Outlook

Various key Postpartum Depression companies are leading the treatment landscape, such as Sage Therapeutics, Marinus Pharmaceuticals, Lipocine, Brii Biosciences, and others. The details of the country-wise and therapy-wise Postpartum Depression market size have been provided below.

• The Postpartum Depression Treatment Market Size in the 7MM was estimated to be USD 260 Million in 2023.
• In the seven major Postpartum Depression Therapeutics Market, SNRI's and SSRI's constituted 20% market share of the overall Postpartum Depression Drugs Market, while Atypical antidepressants and Antipsychotics held 19% market share, in 2023.
• In the 7MM, ZURZUVAE is expected to garner Postpartum Depression Therapeutics market revenue of ~USD 600 million by 2036.
• Among the seven major market, the United States held the highest Postpartum Depression Drugs Market Share (64%) of the overall Postpartum Depression market.
• Among EU4 and the UK, the UK accounted for the highest Postpartum Depression Treatment Market Size was ~USD 25 million in 2023
• Japan accounted for a Postpartum Depression Market Size of ~USD 20 million in 2023, which is expected to increase at a moderate rate by 2036.

Postpartum Depression Pipeline Drugs Market Chapters

The section dedicated to drugs in the Postpartum Depression pipeine drugs market report provides an in-depth evaluation of late-stage Postpartum Depression pipeline drugs (Phase III and Phase II) related to Postpartum Depression. The drug chapters section provides valuable information on various aspects related to Postpartum Depression clinical trials, such as the pharmacological mechanisms of the drugs involved, designations, approval status, patent information, and a comprehensive analysis of the pros and cons associated with each drug. Furthermore, it presents the most recent Postpartum Depression news updates and press releases on drugs targeting Postpartum Depression.

Postpartum Depression Marketed Therapies

• ZURZUVAE (zuranolone) : Sage Therapeutics/Biogen

Zuranolone (SAGE-217) is an investigational, oral, novel medicine in development for postpartum depression (PPD). It is given once daily, a 2-week therapy neuroactive steroid (NAS) GABAA receptor positive allosteric modulator (PAM) specifically designed to relieve several depression disorders, including PPD, major depressive disorder (MDD), and treatment-resistant depression. The GABA system is the major inhibitory signaling pathway of the brain, and the central nervous system (CNS) significantly regulates CNS function. SAGE-217 has been optimized for selectivity to synaptic and extrasynaptic type a Y-aminobutyric acid (GABAA) receptors and a pharmacokinetic profile for daily oral dosing.

• ZULRESSO: Sage Therapeutics

ZULRESSO is a proprietary IV formulation of brexanolone. Brexanolone is chemically identical to allopregnanolone, a naturally occurring neuroactive steroid that acts as a positive allosteric modulator of gamma-aminobutyric acid (GABA) receptors indicated for treating PPD in adults. Brexanolone is available to patients only through a Risk Evaluation and Mitigation Strategy (REMS) program and must be administered at a certified healthcare facility. In addition, patients must be monitored continuously during the drug infusion due to the risk of serious side effects. Notably, ZULRESSO (brexanolone) is the first drug approved by the US FDA specifically for PPD in adults.

The mechanism of action of brexanolone in treating PPD in adults is related to its positive allosteric modulation of GABAA receptors. Brexanolone potentiated GABA-mediated currents from recombinant human GABAA receptors in mammalian cells expressing a1B2Y2 receptor subunits, a4B3δ receptor subunits, and a6B3δ receptor subunits.

Postpartum Depression Emerging Therapies

Luvesilocin (RE104): Reunion Neuroscience

Luvesilocin is an investigational therapy being evaluated for PPD, currently in Phase II clinical development, designed to modulate neuroactive pathways involved in mood regulation. It is expected to initiate a pivotal Phase III clinical trial in 2026, with the aim of improving depressive symptoms and restoring emotional and functional balance in affected individuals.

NORA520: TWi Biotechnology

NORA520 is an investigational therapy being evaluated for adults with PPD, currently in Phase II clinical development. It is designed to target neurobiological pathways involved in mood regulation, aiming to improve depressive symptoms and overall functional outcomes in affected individuals.

LPCN 1154: Lipocine

BRLIZIO (LPCN 1154) is an investigational oral therapy being evaluated for adults with PPD, currently in late-stage clinical development. It is designed to modulate neuroactive hormonal pathways involved in mood regulation, with a new drug application (NDA) submission in the US expected in mid-2026.

Postpartum Depression Market Outlook

Antidepressants, such as Abilify (aripiprazole), Zoloft (sertraline hydrochloride), Spravato (esketamine), Prozac (fluoxetine capsules), Celexa (citalopram hydrobromide), Luvox CR (Fluvoxamine Maleate), and Paxil CR (paroxetine) form the mainstay in the Postpartum Depression treatment. Although these drugs are approved for treating depression-related disorders such as major depressive disorder (MDD), obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), treatment-resistant depression (TRD), etc., they are being used as off-label drugs for the treatment of PPD. The type of medication prescribed by the doctors largely depends on the set of symptoms, severity and the specific type of PPD the patient is suffering from. The primary concern about antidepressants is the uncertainty in the outcomes and their side effects on new born due to breastfeeding. Though antidepressants are not necessarily a permanent cure for PPD, they are an important aspect of managing depression symptoms and restoring quality of life.

Many new molecules with novel mechanisms, like GABAA receptor positive allosteric modulator, allosteric modulator of Y-aminobutyric acid ("GABA") receptor among others, are being developed for the treatment PPD by key players like Sage Therapeutics, Marinus Pharmaceuticals, Lipocine, Brii Biosciences among others.

In conclusion, despite the lack of appropriate treatment in the current Postpartum Depression treatment market landscape, many potential therapies with novel mechanisms are expected to enter the market, resolving a dire Postpartum Depression unmet need and leading to significant improvement in the treatment outcome of Postpartum Depression patients. Hence, with the upcoming availability of new treatment options and increasing healthcare spending across the 7MM, the Postpartum Depression treatment market scenario is expected to experience significant growth during the forecast period (2026-2036).

Latest News

• In February 2026, the last patient completed the final study visit in a confirmatory Phase III trial evaluating LPCN 1154 for PPD, with topline results expected in early April 2026.
• In January 2026, Reunion Neuroscience reported full data from the RECONNECT Phase II clinical trial of RE104 for the treatment of PPD at the ACNP Annual Meeting.
• In January 2026, Lipocine reported completion of a scheduled independent Data Safety Monitoring Board review of its ongoing Phase III trial of LPCN 1154 for PPD, with the study recommended to continue without modification.
• In November 2025, TWi Biotechnology reported results from a Phase II clinical trial of NORA520 for postpartum depression, reporting that the combined treatment groups did not achieve a statistically significant difference compared with placebo, highlighting limited efficacy in this study.
• In October 2025, TWi Biotechnology reported completion of patient enrollment in the Phase II clinical trial of its oral prodrug NORA520 for PPD and major depressive disorder.

Postpartum Depression Treatment Market: Overview

Postpartum depression (PPD) is the most common non-psychotic complication of childbearing affecting approximately 10-15% of women and, as such, represents a considerable public health problem affecting women and their families. The postnatal period is well established as an increased time of risk for the development of serious mood disorders. There are three common forms of postpartum affective illness: the blues (baby blues, maternity blues), postpartum (or postnatal) depression, and puerperal (postpartum or postnatal) psychosis, each of which differs in its prevalence, clinical presentation, and management. The effects of postnatal depression on the mother, her marital relationship, and her children make it an important condition to diagnose, treat, and prevent. Untreated PPD can have adverse long-term effects. For the mother, the episode can be the precursor of chronic recurrent depression. For her children, a mother's ongoing depression can contribute to emotional, behavioral, cognitive, and interpersonal problems in later life.

The association between the postpartum period and mood disturbances has been noted since the time of Hippocrates. Women are at increased risk of developing severe psychiatric illness during the puerperium. Studies have shown that a woman is more likely to be admitted to a psychiatric hospital within the first month postpartum than at any other time. Up to 12.5% of all psychiatric hospital admissions of women occur during the postpartum period.

Postpartum Depression Diagnosis

Screening for postpartum depression should be considered strongly, although evidence supporting universal screening tools is lacking. Patients with known risk factors may be selected for screening with the EPDS. The EPDS is a 10-item self-rated instrument used widely to screen for postpartum depression. The Postpartum Depression diagnosis should be strongly considered in women who score above 12 on the Edinburgh Postnatal Depression Scale, experience symptoms that cause moderate to severe social dysfunction, report any suicidal ideation, or experience symptoms for more than 10 days.

Diagnosing postpartum major depression should also include asking patients about past manic episodes. A history of mania or hypomania may indicate bipolar disorder, requiring specific pharmacologic treatment. Bipolar disorder is also associated with a higher risk of mood episodes postpartum. Two questions that are recommended for screening for past manic episodes are

• "Have you ever had four continuous days when you were feeling so good, high, excited, or hyper that other people thought you were not your normal self, or you got into trouble?" and
• "Have you experienced four continuous days when you were so irritable that you found yourself shouting at people or starting fights or arguments?" Positive responses require referral to a psychiatrist.

Postpartum Depression Treatment

Antidepressant medications, cognitive-behavioral therapy (CBT), and interpersonal therapy are effective in treating Postpartum Depression. Other Postpartum Depression treatments which may be useful include psychodynamic therapy, light therapy, exercise, and yoga, but the current research evidence about the efficacy of such treatment regimens is more preliminary.

• Antidepressant Medication- Postpartum Depression can be treated using a combination of therapy and antidepressant medications. There are certain risks of using antidepressants during pregnancy or breastfeeding. Therefore, the benefits and risks are weighed and analyzed adequately before deciding whether or not to use medications during treatment.
• Psychological and Psychosocial Treatments- Existing research supports the use of psychological treatments (specifically interpersonal therapy, cognitive-behavioral therapy, and psychodynamic psychotherapy) and psychosocial interventions, such as non-directive counseling.
• Non-pharmacologic Treatments- Non-pharmacologic Treatments includes Electroconvulsive therapy, Bright light therapy, Omega-3 fatty acids, Acupuncture and massage.

Postpartum Depression Epidemiology

The Postpartum Depression epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent Population of Maternal Postpartum Depression in the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2022 to 2036.

• In 2025, the total diagnosed prevalent cases of maternal PPD in the 7MM were approximately 1.3 million, and this number is expected to rise during the forecast period, driven by increased awareness, improved screening and diagnosis, as well as factors such as pandemic-related stress, economic pressures, and reduced social support.
• Among the 7MM, the US accounted for the largest share of diagnosed prevalent cases of maternal PPD in 2025, with approximately 700,000 cases, reflecting higher awareness, robust screening practices, and greater access to maternal mental healthcare services.

KOL Views

To stay abreast of the latest trends in the Postpartum Depression treatment market, we conduct primary research by seeking the opinions of Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) who work in the relevant field. This helps us fill any gaps in data and validate our secondary research. We have reached out to industry experts to gather insights on various aspects of Postpartum Depression, including the evolving treatment landscape, patients' reliance on conventional therapies, their acceptance of therapy switching, drug uptake, and challenges related to accessibility.

The experts we contacted included medical/scientific writers, professors, and researchers from prestigious universities in the US, Europe, the UK, and Japan. Our team of analysts at Delveinsight connected with more than 15 KOLs across the 7MM. We contacted institutions such as the University of Nevada, University of Pittsburgh Medical Center, UConn Health Center, Strasbourg University, and Feinstein Institutes for Medical Research etc., among others. By obtaining the opinions of these experts, we gained a better understanding of the current and emerging treatment patterns in the Postpartum Depression management market outlook, which will assist our clients in analyzing the overall epidemiology and market scenario.

Some opinion of experts from various regions has been provided below:

Postpartum Depression Management Market: Qualitative Analysis

We perform Qualitative and Postpartum Depression Pipeline Drugs Market Intelligence analysis using various approaches, such as SWOT analysis and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst's discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.

Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, designation, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy. In efficacy, the trial's primary and secondary outcome measures are evaluated; for instance, in trials for Postpartum Depression, important primary endpoints are overall survival rate, event-free survival, progression free survival, etc. Based on these parameters, the overall efficacy is evaluated.

Further, the therapies' safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the route of administration, order of entry and designation, probability of success, and the addressable patient pool for each therapy. According to these parameters, a final weightage score is decided, based on which the emerging therapies are ranked.

Postpartum Depression Therapeutics Market Access and Reimbursement

Because newly Postpartum Depression authorized drugs are often expensive, some patients escape receiving proper treatment or use off-label, less expensive prescriptions. Reimbursement plays a critical role in how innovative treatments can enter the market. The cost of the medicine, compared to the benefit it provides to patients who are being treated, sometimes determines whether or not it will be reimbursed. Regulatory status, target population size, the setting of treatment, unmet needs, the number of incremental benefit claims, and prices can all affect market access and reimbursement possibilities.

The Postpartum Depression management market outlook report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Postpartum Depression Treatment Market Report Insights

• Patient-based Postpartum Depression Market Forecasting
• Therapeutic Approaches in the Postpartum Depression Management Market
• Postpartum Depression Market Size
• Postpartum Depression Market Trends
• Postpartum Depression Market Outlook
• Existing Postpartum Depression Pipeline Drugs Market Opportunity

Postpartum Depression Treatment Market Report Key Strengths

• 11 Years- Postpartum Depression Market Forecast
• The 7MM Coverage
• Postpartum Depression Epidemiology Segmentation
• Key Cross Competition in the Postpartum Depression Management Market

Postpartum Depression Treatment Market Report Assessment

• Current Postpartum Depression Treatment Market Practices
• Reimbursements
• Postpartum Depression Market Outlook Attractiveness
• Qualitative Analysis (SWOT, Conjoint Analysis, Postpartum Depression Unmet needs)

Key Questions:

• Would there be any changes observed in the current Postpartum Depression treatment market approach?
• Will there be any improvements in Postpartum Depression management market recommendations?
• Would research and development advances pave the way for future tests and Postpartum Depression therapies?
• Would the diagnostic testing space experience a significant impact and lead to a positive shift in the Postpartum Depression treatment landscape?
• What kind of uptake will the new therapies witness in coming years in Postpartum Depression patients?

Table of Contents

1. Key Insights

2. Report Introduction

3. Postpartum Depression Market Overview at a Glance

• 3.1 Market Share (%) Distribution of Postpartum Depression (PPD) by therapies in 2022
• 3.2 Market Share (%) Distribution of Postpartum Depression (PPD) by therapies in 2036

4 Executive Summary of Postpartum Depression

5 Key events

6 Disease Background and Overview

• 6.1 Introduction
• 6.2 Clinical Presentation
• 6.3 Risk Factors
• 6.4 Pathogenesis
• 6.5 Diagnosis and Screening
  • 6.5.1 Diagnostic Criteria

7 Treatment and Management

• 7.1 Antidepressant Medication
• 7.2 Psychological and Psychosocial Treatments
• 7.3 Non-pharmacologic Treatments
• 7.4 Hormone Therapy
• 7.5 Treatment Algorithm
• 7.6 Treatment Guidelines by Unicare
• 7.7 Treatment Guidelines by the National Institute for Health and Care Excellence (NICE)

8 Methodology

9 Epidemiology and Patient Population

• 9.1 Key Findings
• 9.2 Assumptions and Rationale
• 9.3 Total Diagnosed Prevalent Population of Postpartum Depression in the 7MM
• 9.4 Epidemiology Scenario in the United States
  • 9.4.1 Total Diagnosed Prevalent Population of Maternal Postpartum Depression in the United States
• 9.5 Epidemiology Scenario in EU4 and the UK
  • 9.5.1 Total Diagnosed Prevalent Population of Maternal Postpartum Depression in EU4 and the UK
• 9.6 Epidemiology Scenario in Japan
  • 9.6.1 Total Diagnosed Prevalent Population of Maternal Postpartum Depression in Japan

10 Patient Journey

11 Marketed Therapies

• 11.1 Key Cross
• 11.2 ZULRESSO: Sage Therapeutics
  • 11.2.1 Product Description
  • 11.2.2 Regulatory Milestones
  • 11.2.3 Other Developmental Activities
  • 11.2.4 Clinical Developmental Activities
  • 11.2.5 Safety and Efficacy

12 Emerging Therapies

• 12.1 Key Cross
• 12.2 SAGE-217/BIIB-125: Sage Therapeutics/Biogen
  • 12.2.1 Product Description
  • 12.2.2 Other Developmental Activities
  • 12.2.3 Clinical Development
  • 12.2.4 Safety and efficacy
• 12.3 Ganaxolone: Marinus Pharmaceuticals
  • 12.3.1 Product Description
  • 12.3.2 Other Developmental Activity
  • 12.3.3 Clinical Development
  • 12.3.4 Safety and efficacy
• 12.4 LPCN 1154: Lipocine
  • 12.4.1 Product Description
  • 12.4.2 Other Developmental Activity
• 12.5 BRII-296: Brii Biosciences Limited
  • 12.5.1 Product Description
  • 12.5.2 Clinical Development
  • 12.5.3 Safety and efficacy

13 Postpartum Depression (PPD): Seven Major Market Analysis

• 13.1 Key Findings
• 13.2 Market Outlook
• 13.3 Key Market Forecast Assumptions
• 13.4 Total Market Size of Postpartum Depression (PPD) in the 7MM
• 13.5 Market Size of Postpartum Depression (PPD) by Therapies in the 7MM
• 13.6 The United States Market Size
  • 13.6.1 Total Market Size of Postpartum Depression (PPD) in the United States
  • 13.6.2 Market Size of Postpartum Depression (PPD) by Therapies in the United States
• 13.7 EU4 and the UK Market Size
  • 13.7.1 Total Market Size of Postpartum Depression (PPD) in EU4 and the UK
  • 13.7.2 Market Size of Postpartum Depression (PPD) by Therapies in EU4 and the UK
• 13.8 Japan Market Size
  • 13.8.1 Total Market Size of Postpartum Depression (PPD) in Japan
  • 13.8.2 Market Size of Postpartum Depression (PPD) by Therapies in Japan

14 KOL Views

15 SWOT Analysis

16 Unmet Needs

17 Market Access and Reimbursement

• 17.1 The United States
  • 17.1.1 Centre for Medicare and Medicaid Services (CMS)
• 17.2 The EU4 and the UK
  • 17.2.1 Germany
  • 17.2.2 France
  • 17.2.3 Italy
  • 17.2.4 Spain
  • 17.2.5 The United Kingdom
• 17.3 Japan
  • 17.3.1 MHLW

18 Appendix

• 18.1 Bibliography
• 18.2 Report Methodology

19 DelveInsight Capabilities

20 Disclaimer

21 About DelveInsight